The American Diabetes Association® (ADA) will present the 2019 Outstanding Achievement in Clinical Diabetes Research Award to John B. Buse, MD, PhD. This award recognizes exceptional contributions in patient-oriented or clinical outcomes research that have had a significant impact on diabetes prevention and treatment. Dr. Buse will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7–11, 2019, at the Moscone Convention Center in San Francisco. 

Dr. Buse is the Verne S. Caviness Distinguished Professor, Chief of the Division of Endocrinology, Director of the Diabetes Center, Director of the North Carolina Translational and Clinical Sciences Institute, and Executive Associate Dean for Clinical Research at the University of North Carolina School of Medicine. Dr. Buse has also led or participated in more than 200 national and international clinical studies and dozens of epidemiologic analyses and translational projects.

“Dr. Buse’s remarkable contributions have substantially influenced the clinical care of diabetes, from early stage clinical characterization of new molecular entities to seminal clinical trials, including critical drug safety outcomes studies,” said the ADA’s 2019 President of Medicine and Science Louis H. Philipson, MD, PhD, FACP. “We congratulate Dr. Buse and sincerely thank him for his many research contributions, which have shaped the way we approach diabetes care and informed evidence-based strategies to prevent and treat diabetes, as well as our ability to reduce the risks of serious complications including cardiovascular disease.”

Dr. Buse is renowned for co-chairing the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which demonstrated a lack of benefit of more intensive goals for glycemia, blood pressure and lipids, and for chairing the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was the first demonstration of the broad effect of the GLP-1 receptor agonist liraglutide to reduce cardiovascular events and mortality in patients with type 2 diabetes with high cardiovascular risk. Furthermore, he has been listed among Thompson Reuters’ “Highly Cited Researchers” since 2015, which recognizes the top one percent of global investigators, and he is widely sought after as a lecturer, consultant, collaborator and clinical trial investigator.

The American Diabetes Association’s 79th Scientific Sessions, the world’s largest scientific meeting focused on diabetes research, prevention and care, will be held June 7-11, 2019, at the Moscone Center in San Francisco, California. Nearly 15,000 leading physicians, scientists, health care professionals and industry representatives from around the world are expected to convene at the Scientific Sessions to unveil cutting-edge research, treatment recommendations and advances toward a cure for diabetes. During the five-day meeting, attendees will receive exclusive access to more than 850 presentations and 2,000 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight thematic areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Gretchen Youssef, MS, RDN, CDE, President of Health Care and Education, will deliver her address, “It’s All about Access!” on Saturday, June 8, and Louis H. Philipson, MD, PhD, FACP, President of Medicine and Science, will deliver his lecture, “Precision Medicine—Addressing the Many Faces of Diabetes,” on Sunday, June 9. Join the Scientific Sessions conversation on social media using #ADA2019.

# # #